Clinical trial
A Trial of Gemcitabine Combined With Vinorelbine as First Line Chemotherapy for…
NCT00192062 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00192062 |
|---|---|
| Title | A Trial of Gemcitabine Combined With Vinorelbine as First Line Chemotherapy for Metastatic Breast Cancer |
| Official title | A Phase II Trial of Gemcitabine (Gemzar) Combined With Vinorelbine as First Line Chemotherapy for Metastatic Breast Cancer |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | gemcitabine, vinorelbine |
| Enrollment | 80 |
| Start date | Jul 1, 2004 |
| Completion | Jun 1, 2007 |
| First posted | Sep 19, 2005 |
| Last update posted | Aug 31, 2007 |
| Countries | Egypt |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: